Association of Fibroblast Growth Factor 23 and Calcium in Chronic Kidney Disease Patients

Ghaith Hamza Kamil; Mohammed Mezher Hussein; Raya Ezzat Maroof

doi:10.51173/jt.v4i33.656

Authors

Ghaith Hamza Kamil College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq
Mohammed Mezher Hussein College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq
Raya Ezzat Maroof College of Health & Medical Technology - Baghdad, Middle Technical University, Baghdad, Iraq

DOI:

https://doi.org/10.51173/jt.v4i33.656

Keywords:

Chronic kidney disease, Calcium, Fibroblast growth factor 23

Abstract

Chronic kidney disease (CKD) is a growing international health concern with elevating mortality rate in the world today and it is generally a progressive and irreversible issue. It is defined by changes in kidney shape, function, or both lasting at least three months. Renal disease is commonly associated with Abnormalities of minerals and electrolyte. Levels of Ca change and the FGF23 increase early in CKD. This study was designed to show the Correlation between FGF23 and Ca in chronic kidney disease patients. One hundred blood samples (57males and 43 females) from CKD patients have been gathered from Al-Yarmouk Teaching Hospital, Baghdad Teaching Hospital and Al-Karama Teaching Hospital during the period from December 2021 to March 2022 besides 50 samples as apparently healthy control. The age range in the current study was at 33-75 years for CKD patient and 30-65 years for control. The fibroblast growth factor 23 was screened by an ELISA method and serum Calcium, by cobas c111 analyze. Ca, FGF23 is statistically highly significant at p-value =0.001. The receiver operation characteristic (ROC) curve results revealed that the sensitivity and specificity for FGF23 was 100%. The conclusion of the current study shows that the. FGF 23 was high in all CKD patients and Ca was high in two patients, normal in thirty-seven patients, and decreased in sixty-one patients.

Downloads

Download data is not yet available.

References

Portales-Castillo, I. A., YU, E. W., Jüppner, H. & Nigwekar, S. U. Chronic Kidney Disease–Mineral and Bone Disorders. approaches to chronic kidney disease. springer(2022).

Axtell, A. L., Fiedler, A. G., Melnitchouk, S., D'alessandro, D. A., Villavicencio, M. A., Jassar, A. S. & Sundt III, T. M. Correlation of cardiopulmonary bypass duration with acute renal failure after cardiac surgery. The Journal of thoracic and cardiovascular surgery,(2020), 159, 170-178. e2.

Daenen, k., Andries, a., Mekahli, d., van schepdael, a., jouret, F. & Bammens, B. Oxidative stress in chronic kidney disease. Pediatric nephrology,(2019), 34, 975-991.

Van venrooij, n. a., Pereira, r. c., tintut, y., fishbein, m. c., tumber, n., demer, l. l., salusky, I. B. & Wesseling-Perry, K. FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrology Dialysis Transplantation,(2014) 29, 1525-1532.

Beck-Nielsen, S. S., Mughal, Z., Haffner, D., Nilsson, O., Levtchenko, E., ariceta, G., Delucas Collantes, C., Schnabel, D., Jandhyala, R. & Mäkitie, O. FGF23 and its role in X-linked hypophosphatemia-related morbidity. Orphanet journal of rare diseases,(2019), 14, 1-25.

Lang, F., Leibrock, C., Pandyra, A. A., Stournaras, C., Wagner, C. A. & Föller, M. Phosphate homeostasis, inflammation and the regulation of FGF-23. Kidney and Blood Pressure Research,(2018), 43, 1742-1748.

Ramspek, C. L., Evans, M., Wanner, C., Drechsler, C., Chesnaye, N. C., Szymczak, M., Krajewska, M., Torino, C., Porto, G. & Hayward, s. Kidney failure prediction models: a comprehensive external validation study in patients with advanced CKD. Journal of the American Society of Nephrology,(2021), 32, 1174-1186.

Chi, T., Taylor, E. & Stoller, M. L. Making sense of dietary calcium and urinary stone disease. Translational andrology and urology,(2014), 3, 241.

Memon, S., Alam, A., Saeed, F., Chughtai, J., Imtiaz, S., ahmed, S. & tariq, S. Hyperparathyroidism and Associated Factors in Chronic Kidney Disease. European Journal of Clinical Medicine,(2022), 3, 8-12.

Parmar, J. N., Panjwani, M. & Bariya, B. R. Secondary Hyperparathyroidism in Patients with Chronic Renal Failure Attending a Tertiary Health Care Hospital-A Cross-sectional Study in Saurashtra Region of Gujarat, India. Journal of Clinical & Diagnostic Research,(2021), 15.

Belli, M., Martin, R. M., Brescia, M. D. E. G., Nascimento JR, C. P., Massoni neto, L. M., Arap, S. S., Ferraz-DE-souza, B., Moyses, R. M. A., Peacock, M. & Montenegro, F. L. D. M. Acute and long-term kidney function after parathyroidectomy for primary hyperparathyroidism. PLoS One,(2020), 15, e0244162.

Bozic, M., Diaz-Tocados, J. M., Bermudez-Lopez, M., Forné, C., MartineZ, C., Fernandez, E. & Valdivielso, J. M. Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort. Nephrology Dialysis Transplantation,(2022), 37, 663-672.

Alzamanan, M. D., Rayshan, A., Salem, A. & Alyami, A. Risk factors of chronic renal failure in adult patients at King Khalid Hospital, Najran City, Saudi Arabia. The Egyptian Journal of Hospital Medicine,(2018), 70, 88-91.

Carrero, J. J., Hecking, M., Chesnaye, N. C. & Jager, K. J. Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease. Nature Reviews Nephrology,(2018), 14, 151-164.

Athab, A. M., Rashid, B. A. & Mohammed, A. I. Non Significant Difference in Parathyroid Hormone, Calcium or Phosphat Levels Inpatients with Chronic Kidney Disease on Conservative or Replacement Therapeutic Modalities. Indian Journal of Forensic Medicine & Toxicology,(2009), 13.

Thongprayoon, C., Cheungpasitporn, W., Chewcharat, A., Mao, M. A., Bathini, T., Vallabhajosyula, S., Thirunavukkarasu, S. & Kashani, K. B. Impact of admission serum ionized calcium levels on risk of acute kidney injury in hospitalized patients. Scientific reports,(2020), 10, 1-6.

Mahadita, G., Kandarini, Y. & Widiana, i. pos-259 the differences of serum calcium-phosphate product levels and iron status among high and lower fibroblast Growth Factor-23 Levels in regular Hemodialysis Patients. Kidney International Reports,(2022), 7, S114-S115.

Rodelo-Haad, C., Santamaria, R., Muñoz-castañeda, J. R., Pendón-Ruiz De Mier, M., Martin-Malo, A. & Rodriguez, M. FGF23, biomarker or target? Toxins,(2019), 11, 175.

Courbon, G., Francis, C., Gerber, C., Neuburg, S., Wang, X., Lynch, E., Isakova, T., babitt, J. L., Wolf, M. & Martin, A. Lipocalin 2 stimulates bone fibroblast growth factor 23 production in chronic kidney disease. Bone research,(2021), 9, 1-11.

Does, C. hypercalcemia in chronic kidney disease . Department of Comparative Biomedical Sciences, Royal Veterinary College,(2018) ,31:791-798.

Muzasti, R. A. & Lubis, N. D. Diagnostic value of fibroblast growth factor 23 for abdominal aortic calcification in Indonesian hemodialysis patients. Tzu-Chi Medical Journal,(2021), 33, 154.

Palupi-baroto, R., Hermawan, K., Murni, I. K., Nurlitasari, T., Prihastuti, Y., Sekali, D. R. K. & Ambarsari, C. G. High Fibroblast Growth Factor 23 as a Biomarker for Severe Cardiac Impairment in Children with Chronic Kidney Disease: A Single Tertiary Center Study. International Journal of Nephrology and Renovascular Disease,(2021), 14, 165.

Ibrahim, B. O., Tawfik, G. A., Ahmed, H. & Omar, H. H. Association of Fibroblast Growth Factor-23 and Early Detection of Breast Arterial Calcification in Different Stages of Chronic Kidney Disease Patients. Suez Canal University Medical Journal,(2022), 25, 80-91.